Segment Reporting - Schedule of Segment Reporting Information, by Segment (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2024	Sep. 30, 2024	Jun. 30, 2024	Mar. 31, 2024	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total revenues, net	$ 199,223	$ 175,375	$ 161,388	$ 144,866	$ 132,099	$ 126,173	$ 110,792	$ 95,306	$ 680,852	$ 464,370	$ 250,314
Segment Reconciliation [Abstract]
Cost of product sales									56,963	33,745	20,443
Net loss	$ (16,885)	$ (26,324)	$ (16,220)	$ (15,247)	$ (28,579)	$ (24,258)	$ (42,784)	$ (44,053)	(74,676)	(139,674)	(256,256)
Reportable Segment
Segment Reporting Information [Line Items]
Total revenues, net									680,852	464,370
Segment Reconciliation [Abstract]
Cost of product sales									56,963	33,745
SG&A: Selling expenses									384,744	324,499
SG&A: General and administrative expenses									119,745	85,365
R&D: Other and overhead									37,360	30,623
Other segments items									(42,045)	(19,707)
Net loss									(74,676)	(139,674)
Reportable Segment | Lumateperone
Segment Reconciliation [Abstract]
R&D: Lumateperone project costs									138,561	111,881
Reportable Segment | Non-Lumateperone Projects
Segment Reconciliation [Abstract]
R&D: Lumateperone project costs									60,200	37,638
Product
Segment Reporting Information [Line Items]
Total revenues, net									680,501	462,175	249,132
Product | Reportable Segment
Segment Reporting Information [Line Items]
Total revenues, net									680,501	462,175
Grant revenue
Segment Reporting Information [Line Items]
Total revenues, net									351	2,195	$ 1,182
Grant revenue | Reportable Segment
Segment Reporting Information [Line Items]
Total revenues, net									$ 351	$ 2,195